Breast Cancer

View overview page

NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC

Kevin Kalinsky • 22 Oct 2023

5-year monarchE results: abemaciclib + ET in high-risk EBC

Kevin Kalinsky • 22 Oct 2023

The effect of MCED blood tests on patient screening and mental wellbeing

Tom Beer • 22 Oct 2023

Novel treatment options for HER2-low breast cancer

Eva Ciruelos • 23 Oct 2023

Updates in metastatic triple-negative breast cancer at ESMO 2023

Eva Ciruelos • 23 Oct 2023

How can clinicians provide equitable care in breast cancer?

Sarah Adomah • 14 Nov 2023

Addressing inequalities in breast prostheses post-mastectomy

Sarah Adomah • 14 Nov 2023

Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histology

Oleg Gluz • 22 Oct 2023

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023

Adjuvant treatment guidelines in post-menopausal women with breast cancer

Patrick Neven • 23 Oct 2023

BRCA-DIRECT: a digitized information hub for women with BC seeking germline genetic testing

Bethany Torr • 22 Oct 2023

Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancer

Sherene Loi • 20 Oct 2023

CheckMate 7FL: nivo vs PBO in high-risk ER+ HER2- BC with neoadjuvant chemo and adjuvant therapy

Sherene Loi • 20 Oct 2023

ESMO 2023: Key messages for breast cancer treatment

Kevin Kalinsky • 21 Oct 2023

Challenges in identifying predictive markers to ICIs in triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023

Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer

Kevin Kalinsky • 21 Oct 2023

1
2
3
4
5
…
72
Next